BDTX
NASDAQBlack Diamond Therapeutics
$2.28
-1.27 (-35.77%)
2026-05-22 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$163.9M
P/E Ratio
6.8
52W Low
52W High
$1.93
$4.94
Volume
8.2M
Analyst Rating
Hold
Target: $10
8 Analyst Ratings
Strong Buy
0
Buy
0
Hold
8
Sell
0
Price Target Range
Low: $9
Avg: $10
High: $10
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also dev...
Employees
21
Website
blackdiamondtherapeutics.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $70.0M | 28.4% | $22.4M | $29.6M |
| 2024 | N/A | N/A% | -$69.7M | -$62.3M |
| 2023 | N/A | N/A% | -$82.4M | -$66.7M |
| 2022 | N/A | N/A% | -$91.2M | -$84.9M |
| 2021 | N/A | N/A% | -$125.6M | -$97.4M |
| 2026 Q1 | N/A | N/A% | -$9.0M | -$10.2M |
| 2025 Q4 | N/A | N/A% | -$15.1M | -$6.8M |
| 2025 Q3 | N/A | N/A% | -$8.5M | -$7.8M |
| 2025 Q2 | N/A | N/A% | -$10.6M | -$9.2M |
| 2025 Q1 | $70.0M | 77.9% | $56.5M | $53.4M |
| 2024 Q4 | $516K | -3541.7% | -$16.0M | -$15.1M |
| 2024 Q3 | N/A | N/A% | -$15.6M | $3.4M |
| 2024 Q2 | N/A | N/A% | -$19.9M | N/A |